Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
HIMS 
Hims Hers Health Inc (HIMS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/04/2025: HIMS (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
13 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $44.82
1 Year Target Price $44.82
| 4 | Strong Buy |
| 1 | Buy |
| 6 | Hold |
| 1 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 104.16% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 12/04/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 8.44B USD | Price to earnings Ratio 69.94 | 1Y Target Price 44.82 |
Price to earnings Ratio 69.94 | 1Y Target Price 44.82 | ||
Volume (30-day avg) 13 | Beta 2.4 | 52 Weeks Range 23.97 - 72.98 | Updated Date 12/4/2025 |
52 Weeks Range 23.97 - 72.98 | Updated Date 12/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.53 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 6.05% | Operating Margin (TTM) 2.06% |
Management Effectiveness
Return on Assets (TTM) 5.56% | Return on Equity (TTM) 26.21% |
Valuation
Trailing PE 69.94 | Forward PE 56.18 | Enterprise Value 8927209413 | Price to Sales(TTM) 3.82 |
Enterprise Value 8927209413 | Price to Sales(TTM) 3.82 | ||
Enterprise Value to Revenue 4.04 | Enterprise Value to EBITDA 56.68 | Shares Outstanding 219270891 | Shares Floating 206149388 |
Shares Outstanding 219270891 | Shares Floating 206149388 | ||
Percent Insiders 6.29 | Percent Institutions 94.34 |
Upturn AI SWOT
Hims Hers Health Inc
Company Overview
History and Background
Hims Hers Health Inc., was founded in 2017 by Andrew Dudum. Initially focused on men's health (Hims), it expanded to women's health (Hers) and went public in 2021 via a SPAC merger. It's evolved into a telehealth platform offering personalized health and wellness solutions.
Core Business Areas
- Men's Health (Hims): Offers prescription and over-the-counter products for hair loss, erectile dysfunction, and skincare.
- Women's Health (Hers): Provides treatments for skincare, birth control, and mental health.
- Mental Health: Offers therapy and medication for anxiety and depression.
- Virtual Primary Care: Provides primary care consultations and prescriptions through its platform.
Leadership and Structure
Andrew Dudum is the CEO. The company operates with a functional organizational structure, emphasizing marketing, technology, and healthcare operations.
Top Products and Market Share
Key Offerings
- Hair Loss Treatments (Finasteride, Minoxidil): Prescription and over-the-counter hair loss solutions. Competitors include Keeps, Ro, and manual. Market share is difficult to pinpoint but is significant as one of the first entrants.
- Erectile Dysfunction Medication (Sildenafil, Tadalafil): Generic and branded erectile dysfunction medications. Competitors include Ro, Viagra (Pfizer), and Cialis (Eli Lilly). Market share is also difficult to pinpoint, with Ro and Viagra likely having larger market shares
- Skincare Products: Range of skincare products addressing acne, aging, and other skin conditions. Competitors include Curology and Dermatica.
- Mental Health Services: Online therapy and medication management for mental health conditions. Competitors include Talkspace and BetterHelp.
Market Dynamics
Industry Overview
The telehealth industry is growing rapidly due to increased demand for convenient and affordable healthcare. Regulations surrounding telehealth are evolving, and competition is increasing.
Positioning
Hims Hers Health Inc. positions itself as a digital health platform offering personalized and accessible healthcare solutions. Its competitive advantage lies in its strong branding, direct-to-consumer marketing, and vertically integrated platform.
Total Addressable Market (TAM)
The TAM for telehealth is estimated to be in the hundreds of billions of dollars, encompassing various healthcare services. Hims Hers Health Inc. is positioned to capture a portion of this market through its focus on specific health conditions and its subscription-based model.
Upturn SWOT Analysis
Strengths
- Strong brand recognition
- Direct-to-consumer marketing expertise
- Vertically integrated telehealth platform
- Subscription-based revenue model
Weaknesses
- Dependence on digital marketing
- Concerns about the quality of care
- Regulatory risks
- Profitability concerns
Opportunities
- Expansion into new healthcare verticals
- Partnerships with healthcare providers
- International expansion
- Increased adoption of telehealth
Threats
- Increased competition
- Changes in regulations
- Negative publicity
- Data breaches
Competitors and Market Share
Key Competitors
- CVS (CVS)
- AMZN (AMZN)
- TDOC (TDOC)
- VRX (BHC)
Competitive Landscape
Hims Hers Health Inc. competes with established telehealth providers and traditional healthcare companies. Its advantages include its strong brand and direct-to-consumer model. Disadvantages include its relatively small scale and lack of profitability compared to larger competitors.
Major Acquisitions
Apostrophe
- Year: 2021
- Acquisition Price (USD millions): 0
- Strategic Rationale: Acquisition of custom prescription skincare company Apostrophe to expand skincare offerings.
Growth Trajectory and Initiatives
Historical Growth: Hims Hers Health Inc. has experienced rapid revenue growth since its inception. Growth has slowed in recent quarters as the company focuses on achieving profitability.
Future Projections: Analysts expect revenue to continue growing, but at a slower pace. The company is projected to achieve profitability in the coming years.
Recent Initiatives: Expanding into new healthcare verticals, partnerships with healthcare providers, and focusing on efficiency and cost reduction.
Summary
Hims Hers Health Inc. is a rapidly growing telehealth company with a strong brand and a vertically integrated platform. Its revenue growth is impressive, but the company is not yet profitable and faces increasing competition. The company must execute its strategy effectively and manage costs to achieve long-term success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings (SEC), Analyst reports, Market research reports, Company press releases
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Market share data is estimated and may not be precise. Analyst estimates are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Hims Hers Health Inc
Exchange NYSE | Headquaters San Francisco, CA, United States | ||
IPO Launch date 2019-09-13 | Co-Founder, Chairman & CEO Mr. Andrew Dudum | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 1637 | Website https://www.hims.com |
Full time employees 1637 | Website https://www.hims.com | ||
Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, sexual health and wellness, skincare, and hair care. In addition, the company's curated non-prescription products include melatonin and biotin in the wellness specialty category; moisturizers, creams, sunscreen, serum, face oil, and face wash in the skincare specialty; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness specialty; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care specialty category. Further, it offers medical consultation and post-consultation support services, as well as health and wellness products through wholesale partners. The company also provides Labs which measures key markers over time and provides doctor-developed action plans. Hims & Hers Health, Inc. is based in San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.